Spironolactone and Sildenafil Interaction: What Clinicians and Patients Should Know

Spironolactone (brand name Aldactone) is a potassium-sparing diuretic and aldosterone antagonist used off-label for hormonal acne and hirsutism at 25 to 200 mg daily, and on-label for heart failure with reduced ejection fraction at 12.5 to 50 mg daily. Sildenafil (brand name Viagra; also marketed as Revatio for pulmonary arterial hypertension) is a phosphodiesterase type 5 (PDE5) inhibitor. This article covers the pairing of oral spironolactone with oral sildenafil, not spironolactone with nitrates or with other PDE5 inhibitors such as tadalafil, which behave somewhat differently.

Content pending qualified clinical review before publication.

Direct answer

Spironolactone and sildenafil are not contraindicated together. Both drugs independently lower blood pressure through unrelated mechanisms, spironolactone through volume and aldosterone effects and sildenafil through vasodilation, so the combination is classified in major interaction databases as a moderate pharmacodynamic interaction requiring monitoring rather than avoidance, per sildenafil prescribing information. This is a different and much lower-risk pairing than sildenafil with nitrates, which remains an absolute contraindication because both act on the same nitric oxide-cGMP pathway. There is no published pharmacokinetic study specific to spironolactone plus sildenafil that would establish a level of blood pressure drop for this exact pair; the reasoning below is extrapolated from each drug's separate hemodynamic profile, and a prescriber should treat the combined effect as additive rather than precisely quantified.

Who actually encounters this combination

The direct co-prescription question arises mainly in two groups: men with heart failure who are prescribed both spironolactone (for mortality benefit) and sildenafil (for erectile dysfunction or pulmonary hypertension), and transgender women taking spironolactone as an anti-androgen who also use a PDE5 inhibitor. Women taking spironolactone at acne doses (25 to 150 mg daily) are far less likely to be co-prescribed sildenafil, and the hemodynamic stakes are lower at those doses.

Why additive hypotension is the central concern

Spironolactone's mineralocorticoid receptor antagonism blocks sodium reabsorption and potassium excretion in the distal nephron, producing natriuresis and mild diuresis; in heart failure, doses in the RALES trial were also associated with reduced aldosterone-driven myocardial fibrosis, a mechanism separate from its diuretic effect (Pitt et al., RALES, N=1,663; approximately a 30% relative reduction in all-cause mortality versus placebo, https://pubmed.ncbi.nlm.nih.gov/10471456/). Some reviews of spironolactone for hypertension have reported meaningful systolic blood pressure lowering across dose ranges used for that indication, though a specific supporting citation could not be confirmed here, and the acne-dose population was not the focus of that literature; its blood pressure effect at 50 to 150 mg for acne has not been separately quantified in the trials cited here.

Sildenafil inhibits PDE5, raising cyclic GMP in vascular smooth muscle and causing vasodilation, predominantly pulmonary and penile but also systemic. Sildenafil prescribing information states that the drug produced transient decreases in supine blood pressure in clinical trials. Peak plasma concentration, and therefore peak hemodynamic effect, occurs 30 to 120 minutes after dosing, with a half-life of roughly 3 to 5 hours.

Because the two drugs act on separate systems, effects are additive rather than a metabolic interaction. This is a pharmacologically plausible mechanism supported by each drug's individual labeling, but it has not been directly tested as a combination in a dedicated interaction trial identified in the sources reviewed for this article.

Established, plausible, and unproven: an evidence-status assessment

What a clinician or pharmacist should verify before relying on this pairing in an individual patient: the patient's baseline orthostatic vitals, current total antihypertensive burden (not just spironolactone), renal function and recent potassium, hepatic status if cirrhotic, and whether any other vasodilating or QT-affecting drug is also present. None of these checks are drug-interaction-database items; they are clinical judgment calls this article cannot make for an individual patient.

Potassium and electrolyte monitoring

Spironolactone's potassium-sparing effect is a separate concern from the blood pressure interaction and exists whether or not sildenafil is added. In RALES, serious hyperkalemia (potassium above 6.0 mmol/L) occurred in about 2% of spironolactone-treated patients versus 1% on placebo (https://pubmed.ncbi.nlm.nih.gov/10471456/). A population-based Canadian study published after RALES found that hyperkalemia-related hospitalizations rose sharply once spironolactone use increased in routine heart failure care outside trial-level monitoring, underscoring that real-world potassium surveillance often lagged behind trial protocols (Juurlink et al., 2004, https://pubmed.ncbi.nlm.nih.gov/15295047/).

Sildenafil is not known to alter potassium excretion directly. A hypotensive episode from the combination could theoretically reduce renal perfusion and blunt potassium excretion, but this specific pathway has not been measured in a published study of the combination and should be treated as a plausible mechanism, not a quantified risk.

For a patient starting sildenafil while on spironolactone, checking a basic metabolic panel at baseline and again within one to two weeks is a reasonable extension of the monitoring already recommended by heart failure guidelines whenever a medication affecting the renin-angiotensin-aldosterone system changes (2017 ACC/AHA/HFSA focused update, https://pubmed.ncbi.nlm.nih.gov/28461007/).

Dose considerations

No regulatory label specifies a dose adjustment for the spironolactone-sildenafil pair specifically. Sildenafil prescribing information recommends a 25 mg starting dose when co-administered with alpha-blockers because of additive hypotension risk. Spironolactone is not an alpha-blocker and its own hemodynamic effect is generally smaller, but applying similar caution, a starting dose of 25 mg sildenafil is a reasonable clinical judgment when a patient is on spironolactone 100 mg or higher, or on any dose of spironolactone plus additional antihypertensives. This is extrapolation from the alpha-blocker precedent, not a spironolactone-specific label instruction, and should be treated as site judgment rather than an established rule.

One small trial of add-on sildenafil in patients with chronic heart failure, most of whom were already on standard heart failure therapy including spironolactone in a majority of participants, reported an additional reduction in blood pressure with sildenafil on top of existing therapy (Guazzi et al., https://pubmed.ncbi.nlm.nih.gov/15607396/). The exact magnitude reported in that trial should be confirmed against the primary paper before being quoted as a specific number in patient materials; this article treats it as directional evidence that add-on sildenafil produces a measurable additional blood pressure effect in heart failure patients on background aldosterone antagonist therapy, not as a precise, generalizable figure.

Women taking spironolactone 25 to 100 mg for acne have a smaller hemodynamic burden from the drug itself. If sildenafil is indicated in this population for an unrelated reason, standard sildenafil dosing can typically proceed with routine blood pressure monitoring, though this specific scenario has not been studied directly.

Distinguishing this from the nitrate interaction

Patients sometimes conflate any blood-pressure-lowering drug with the nitrate-sildenafil contraindication. Sildenafil prescribing information explicitly contraindicates concomitant nitrate use but does not list potassium-sparing diuretics or aldosterone antagonists as contraindicated. The nitrate interaction is synergistic and can be fatal because nitrates and PDE5 inhibitors converge on the same nitric oxide-cGMP pathway; the spironolactone interaction is additive across two separate pathways and is managed with monitoring, not avoidance. Published reviews of PDE5 inhibitor drug interactions are generally understood to describe the hemodynamic interaction with non-nitrate antihypertensives as modest and manageable with monitoring, in contrast to the nitrate contraindication, though a specific supporting reference could not be confirmed for this article; readers should treat any specific attributed wording from secondary reviews as needing direct verification against the original source rather than as a verbatim quotation.

Patient counseling points

Advise patients to sit for 30 seconds before standing after taking sildenafil, particularly in the first few hours post-dose when plasma levels peak. Warning signs of symptomatic hypotension include dizziness, lightheadedness, visual dimming, or near-fainting.

Dehydration worsens both spironolactone's volume-depleting effect and sildenafil's vasodilation, and alcohol adds a third hypotensive mechanism. Sildenafil prescribing information warns that substantial alcohol consumption (5 or more standard drinks) with sildenafil increases the potential for orthostatic symptoms.

Patients should seek urgent evaluation for fainting, a sustained heart rate above 120 bpm, or chest pain after taking sildenafil while on spironolactone. These symptoms may indicate clinically significant hypotension or a cardiac event unrelated to the interaction, and should not be self-managed.

Special populations

Older adults. Sildenafil clearance is reduced in adults over 65, and this population is also more prone to orthostatic hypotension from age-related baroreceptor changes. A conservative 25 mg starting dose is reasonable regardless of spironolactone dose, per general labeling guidance for older adults.

Hepatic impairment. Spironolactone is hepatically metabolized and its active metabolite canrenone can accumulate in cirrhosis, the same population that frequently receives spironolactone for ascites. Sildenafil exposure increases substantially in Child-Pugh class B cirrhosis according to its prescribing information. A conservative starting dose and close monitoring are appropriate in this group; specific combined dosing has not been studied.

Renal impairment. Spironolactone is generally avoided when creatinine clearance falls below 30 mL/min because of hyperkalemia risk. Sildenafil pharmacokinetics are not significantly altered in mild to moderate renal impairment, but exposure rises in severe impairment. If both drugs are used in moderate renal impairment, checking potassium within the first few days of co-initiation is a reasonable precaution, though not a formally validated protocol for this specific pairing.

Alternatives when the combination is unacceptable

For acne, switching from oral spironolactone to a topical anti-androgen or to a combined oral contraceptive is an option some clinicians consider, per AAD acne guidance, though this is a treatment substitution decision that should be made with a prescriber rather than inferred from this article (https://pubmed.ncbi.nlm.nih.gov/38300170/).

For erectile dysfunction, daily low-dose tadalafil is sometimes preferred over on-demand sildenafil in patients sensitive to blood pressure swings, because steady-state dosing avoids sharp peaks, though the specific comparative hemodynamic data cited for that claim in some reviews concerns tadalafil's interaction with alpha-blockers rather than a head-to-head comparison with spironolactone plus sildenafil, and should not be read as a direct equivalence (https://pubmed.ncbi.nlm.nih.gov/15540759/). Vacuum erection devices or intracavernosal alprostadil avoid the systemic vasodilatory mechanism entirely and may be reasonable alternatives for patients who cannot tolerate any PDE5 inhibitor.

Patients on spironolactone for heart failure should not discontinue it to accommodate sildenafil, given its demonstrated mortality benefit in RALES (https://pubmed.ncbi.nlm.nih.gov/10471456/). Dose-adjusted sildenafil with orthostatic precautions is the more appropriate path, decided together with the prescribing cardiologist.

What remains uncertain

There is no identified dedicated pharmacokinetic or outcomes trial studying spironolactone and sildenafil together. All guidance on additive hypotension, dose thresholds, and monitoring timing in this article is extrapolated from each drug's individual FDA labeling and general hypertension pharmacology, not from a combination-specific study. A pharmacist or prescriber reviewing this pairing for an individual patient should verify current interaction database entries directly (Lexicomp, Micromedex) rather than relying solely on this summary, and should confirm any numeric claim quoted from a secondary review against the primary trial before repeating it in a patient-facing document.